Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report

[1] Ferlay J(2019)Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int J Cancer 144 1941-1953

[2] Colombet M(2009)Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063-1069

[3] Soerjomataram I(2018)Checkpoint blockade in esophagogastric cancer J Surg Oncol 118 77-85

[4] Mathers C(2018)Cancer immunotherapy using checkpoint blockade Science. 359 1350-1355

[5] Parkin DM(2017)Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet. 390 2461-2471

[6] Piñeros M(2016)Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Gastric Cancer 19 329-338

[7] Boku N(2018)Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy BMC Cancer 18 1116-347

[8] Yamamoto S(2018)Surgery with curative intent for stage IV gastric cancer: is it a reality of illusion? Ann Gastroenterol Surg 2 339-247

[9] Fukuda H(2019)Conversion surgery for stage IV gastric cancer Front Oncol 9 1158-697

[10] Shirao K(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-1235

[1] Ferlay J(2019)Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int J Cancer 144 1941-1953

[2] Colombet M(2009)Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063-1069

[3] Soerjomataram I(2018)Checkpoint blockade in esophagogastric cancer J Surg Oncol 118 77-85

[4] Mathers C(2018)Cancer immunotherapy using checkpoint blockade Science. 359 1350-1355

[5] Parkin DM(2017)Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet. 390 2461-2471

[6] Piñeros M(2016)Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Gastric Cancer 19 329-338

[7] Boku N(2018)Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy BMC Cancer 18 1116-347

[8] Yamamoto S(2018)Surgery with curative intent for stage IV gastric cancer: is it a reality of illusion? Ann Gastroenterol Surg 2 339-247

[9] Fukuda H(2019)Conversion surgery for stage IV gastric cancer Front Oncol 9 1158-697

[10] Shirao K(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-1235